Introduction to in vivo MRS of cancer: New perspectives and open problems

Anticancer Research

Volumn 16, Issue 3 B, 1996, Pages 1503-1514

  Leach, M O ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Nuclear magnet resonance; Response to therapy; Spectroscopy; Treatment

Indexed keywords

BRAIN TUMOR; CANCER DIAGNOSIS; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; INSTRUMENTATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS;

EID: 0030039136     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (104)

1. 31P magnetic resonance. J Biol Chem 248: 7276-7278, 1973.
2. 31P nuclear magnetic resonance. Nature 252: 285-287, 1974.
3. 31P NMR using surface coils. Nature 283: 167-170, 1980.
4. 31p topical magnetic resonance spectroscopy. Nature 287: 736-738, 1980.
5. Gadian D: "NMR and its applications to living systems." Clarendon Press: Oxford, 1982.
6. de Certaines JD, Bovee WMMJ, Podo F: "Magnetic resonance spectroscopy in biology and medicine." Oxford: Pergamon Press, 1992.
7. Leach MO: Spatially localised nuclear magnetic resonance. In Webb S: (ed): "The physics of medical imaging." Institute of Physics Publishing: Bristol, 1988, 389-487.
8. Gallis J, Canioni P: MRS of the liver. In de Certaines JD, Bovee WMMJ, Podo F: (eds): "Magnetic resonance spectroscopy in biology and medicine. Functional and pathalogical tissue characterization." Oxford: Pergamon Press, 1992, 345-368.
9. Bates TE, Williams SR, Gadian DG: Phosphodiesters in the liver: the effect of field strength on the 31PPP signal. Magn Reson Med 12: 145-150, 1989.
10. Murphy EJ, Rajagopalan B, Bridle KM, Radda G: Phospholipid bilayer contributions to 31PPP NMR spectra in vivoPP. Magn Reson Med 12:282-289, 1989.
11. Leach MO, Le Moyec L, Podo F: MRS of Tumours: Basic Principles. In de Certaines JD, Bovee WMMJ, Podo F: (eds): "Magnetic Resonance Spectroscopy in Biology and Medicine. Functional and Pathological Tissue Characterization." Oxford: Pergamon Press Ltd., 1992, 295-344.
12. Henriksen O: MRS of brain. In de Certaines JD, Bovee WMMJ, Podo F: (eds): "Magnetic Resonance Spectroscopy in Biology and Medicine. Functional and Pathological Tissue Characterization." Oxford: Pergamon Press Ltd., 1992, 411-435.
13. Leach MO: Magnetic resonance spectroscopy applied to clinical oncology. Health Care Tech 2: 235-246, 1994.
14. Leach MO: Practicalities of localization in animal and human tumours. NMR in Biomed 5: 244-252, 1992.
15. Ordidge RJ, Connelly A, Lohman JAB: Image selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J Magn Reson 66: 283-294, 1986.
16. Frahm J, Merboldt KD, Hanicke W: Localized proton spectroscopy using stimulated echoes. J Magn Reson 72: 502-508, 1987.
17. Bottomley PA: "Selective volume method for performing localized NMR spectroscopy." U S Patent 4 480 228, 1984.
18. Ordidge RJ, Beidde MR, Gordon RE, Connelly A: Volume selection for in vivo biological spectroscopy. In Govil K. Sarar T: (eds): "Magnetic Resonance in Biology and Medicine." New Delhi, India: McGraw Hill Publishing Co. Ltd., 1985, 387
19. Kimmich R, Hoepfel D: Volume selective multipulse spin-echo spectroscopy. J Magn Reson 72: 375-384, 1987.
20. Brown TR, Kincaid BM, Ugurbil K: NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci USA 79: 3523-3526, 1982.
21. Keevil SF, Barbiroli B, Collins DJ, Danielsen ER, Hennig J, Henriksen O, Leach MO, Longo R, Lowry M, Moore C, Segebarth C, Bovée WMMJ, Podo F: Quality assessment in in vivo NMR spectroscopy. IV. A multicentre trial of test objects and protocols for performance assessment in clinical NMR spectroscopy. Magn Reson Imag 13: 139-157, 1995.
22. Leach MO, Arnold D, Brown TR, Charles HC, de Certaines JD, Evelhoch JL, Margulis AR, Negendank WG, Nelson SJ, Podo F, Styles P, Shtern F: International workshop on standardization in clinical magnetic resonance spectroscopy measurements: proceedings and recommendations. Academic Radiology 1: 171-186, 1994.
23. Mountford CE, Mackinnon WB, Delikatny EJ, Russell P: High resolution proton MRS in cancer pathology. In de Certaines JD, Bovee WMMJ, Podo F: (eds): "Magnetic Resonance Spectroscopy in Biology and Medicine. Functional and Pathological Tissue Characterization." Pergamon Press Ltd.: Oxford, 1992, 507-527.
24. Bell DJ: MRS of body fluids. In de Certaines JD, Bovee WMMJ, Podo F: (eds): "Magnetic Resonance Spectroscopy in Biology and Medicine. Functional and Pathological Tissue Characterization." Oxford: Pergamon Press Ltd., 1992, 529-558.
25. Seguin F, Le Pape A, Williams SR: MRS of cells. In de Certaines JD, Bovee WMMJ, Podo F: (eds): "Magnetic Resonance Spectroscopy in Biology and Medicine. Functional and Pathological Tissue Characterization." Oxford: Pergamon Press Ltd., 1992, 479-492.
26. Negendank WG, Brown TR, Evelhoch JL, Griffiths JR, Liotta LA, Margulis AR, Morrisett JD, Ross BD, Shtern F: Proceedings of a National Cancer Institute workshop: MR spectroscopy and tumor cell biology. Radiology 185: 875-883, 1992.
27. Negendank W: Studies of human tumors by MRS: a review. NMR in Biomed 5: 303-324, 1992.
28. 31P NMR spectroscopy. Magn Reson Med 11: 1-21, 1989.
29. Sharp JC, Leach MO: Conformal NMR spectroscopy: accurate localization to non cuboidal volumes with optimum SNR. Magn Reson Med 11: 376-388, 1989.
30. Maudsley AA, Hilal SK, Perman WH, Simon HE: Spatially resolved high resolution spectroscopy by "four-dimensional" NMR.. J Magn Reson 51: 147-152, 1983.
31. Brown T: Practical applications of chemical shift imaging. NMR Biomed 5: 238-243, 1992.
32. 1H NMR spectroscopy using an EEC localization test object. Phys Med Biol 40: 1293-1303, 1995.
33. 31 P nuclear magnetic resonance spectroscopy: a review. Cancer Res 49: 4075-4085, 1989.
34. Negendank W: Studies of human tumours by MRS: a review. NMR Biomed 5: 303-324, 1992.
35. Howe FA, Maxwell RJ, Saunders DE, Brown MM, Griffiths JR: Proton spectroscopy in vivo. Magn Reson Q 9: 31-59, 1993.
36. de Certaines J, Larsen VA, Podo F, Carpinelli G, Briot O, Henriksen O: In vivo 31P MRS of Experimental Tumours. NMR in Biomed 6: 345-365, 1993.
37. Warden CH, Friedkin M: Regulation of phosphatidylcholine biosynthesis by mitogenic growth factors. Biochem Biophys Acta 792: 270-280, 1984.
38. 31P NMR spectroscopy. J Biol Chem 262: 14875-14878, 1987.
39. Ko KWS, Cook HW, Vance DE: Reduction of phosphotidylcholine turnover in a Nb 2 lymphoma cell line after prolactine treatment. J Biol Chem 261: 7846-7852, 1986.
40. Smith TAD, Eccles S, Ormerod MG, Tombs AJ, Titley JC, Leach MO: The phosphocholine and glycerophosphocholine content of an oestrogen sensitive rat mammary tumour correlates strongly with growth rate. Br J Cancer 64: 821-826, 1991.
41. Aiken NR, Gillies RG: Phosphomonoester metabolism as a function of cell proliferative status. Anticancer Res 16: 1393-1398, 1996.
42. Ronen SM, Stier A, Degani H: NMR studies of the lipid metabolism of T47D human breast cancer spheroids. FEBS-letters 266: 147-149, 1990.
43. Freyer JP: Response to therapeutic treatment of multicellular tumor spheroids monitored by phosphorus NMR spectroscopy. Proc 3rd Annual Meeting of the SMR and the 12th Annual Meeting of the ESMRMB, Nice. 1701 1995.
44. 31P MRS of human tumor cells: effects of culture media and conditions on phospholipid metabolite concentrations. Anticancer Res 16: 1365-1374, 1996.
45. Barnard ML, Nunn AVM, Bhakoo K, Thomas EL, Bell JD: Analysis of apoptosis by 1H NMR spectroscopy: modulation with cytokines and identification of signalling pathways. Anticancer Research 15: 1692, 1995.
46. Engelmann J, Henke J, Willker W, Kutscher B, Nobner G, Leibfritz D: Early stage monitoring of miltefosine apoptosis in KB cells by multinuclear NMR spectroscopy. Anticancer Res 16: 1429-1440, 1996.
47. Gyngell ML, Hoehn Berlage M, Kloiber O, Michaelis T, Ernestus RI, Horstermann D, Frahm J: Localized proton NMR spectroscopy of experimental gliomas in rat brain in vivo. NMR Biomed 5: 335-340, 1992.
48. Gyngell ML, Els T, Hoehn Berlage M, Hossmann KA: Proton MR spectroscopy of experimental brain tumors in vivo. Acta Neurochir Suppl Wien 60: 350-352, 1994.
49. 1H NMR spectroscopical and histological characterization of a human brain tumor model in the nude rat; a new approach to monitor changes in tumor metabolism. J Neurooncol 13: 119-130, 1992.
50. Remy C, Arus C, Ziegler A, Lai ES, Moreno A, Le Fur Y, Decorps M: in vivo, ex vivo, and in vitro one- and two-dimensional nuclear magnetic resonance spectroscopy of an intracerebral glioma in rat brain: assignment of resonances. J Neurochem 62: 166-179, 1994.
51. 1H NMR studies on rat astrocytes and C6 glioma cells in culture. Biochimie 74: 919-930, 1992.
52. Pianet I, Canioni P, Labouesse J, Merle M: Beta-adrenergic stimulation of C6 glioma cells: effects of cAMP overproduction on cellular metabolites. A multinuclear NMR study. Eur J Biochem 209: 707-715, 1992.
53. 1H NMR spectrum of a human glioma line. Magn Reson Imaging 12: 945-950, 1994.
54. 31P NMR analyses of phosphocholine metabolism in rat glioma cells. Magn Reson Med 32: 310-318, 1994.
55. Barker PB, Blackband SJ, Chatham JC, Soher BJ, Samphilipo MA, Magee CA, Hilton JD, Strandberg JD, Anderson JH: Quantitative proton spectroscopy and histology of a canine brain tumor model. Magn Reson Med 30: 458-464, 1993.
56. Anderson JH, Strandberg JD, Wong DF, Conti PS, Barker PB, Blackband SJ, Hilton J, Natarajan TK, Dannals RF, Samphilipo MAJ, Magee CA, Burckhardt DD: Multimodality correlative study of canine brain tumors: proton magnetic resonance spectroscopy, positron emission tomography, and histology. Invest Radiol 29: 597-605, 1994.
57. 1H NMR and HPLC. Int J Pancreatol 13: 175-185, 1993.
58. 1H NMR spectroscopy of subcutaneous tumors in mice: preliminary studies of effects of growth, chemotherapy and blood flow reduction. NMR Biomed 5: 296-302, 1992.
59. Cornel EB, Heerschap A, Smits GA, Oosterhof GO, Debruyne FM, Schalken JA: Magnetic resonance spectroscopy detects metabolic differences between seven Dunning rat prostate tumor sublines with different biological behavior. Prostate 25: 19-28, 1994.
60. 1H magnetic resonance spectroscopy. Int J Cancer 59: 248-261, 1994.
61. Lean CL, Mackinnon WB, Delikatny EJ, Whitehead RH, Mountford CE: Cell-surface fucosylation and magnetic resonance spectroscopy characterization of human malignant colorectal cells. Biochemistry (USA) 31: 11095-11105, 1992.
62. Le Moyec L, Tatoud R, Eugene M, Gauville C, Primot I, Charlemagne D, Calvo F: Cell and membrane lipid analysis by proton magnetic resonance spectroscopy in five breast cancer cell lines. Br J Cancer 66: 623-628, 1992.
63. 13C NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta 1138: 203-212, 1992.
64. 13C NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta 1095: 5-16, 1991.
65. Tatoud R, Le Moyec L, Gauville C, Degeorges A, Eugene M, Calvo F: Variations in metabolites and lipids detected by proton magnetic resonance spectroscopy (MRS) on drug-sensitive and multidrug-resistant cancer cells (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 33: A2736, 1992.
66. Podo F, Carpinelli G, Ferretti A, Borghi P, Belardelli F: Magnetic resonance spectroscopy studies on phospholipid metabolism in tumor cells and tissues (meeting abstract). Anticancer Res 12: 1849 1992.
67. 14C-radiolabelled compounds in vivo. Biochim Biophys Acta 1181: 111-121, 1993.
68. 31P magnetic resonance studies of energy metabolism and phospholipid pathways. Immunomethods 4: 139-147, 1994.
69. Hui KK, Fossel ET: Alpha-thrombin enhanced phosphatidylserine and phosphatidylethanolamine hydrolysis in ccl 39 cells (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 35: A480, 1994.
70. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. New Engl J Med 312: 1500-1505, 1985.
71. 31P NMR spectra from human breast tumours: variations in phospholipid metabolism. Br J Cancer 63: 514-516, 1991.
72. 31P MR spectroscopy. The Breast 3: 20-23, 1994.
73. Negendank W, Li C-W, Padavic-Shaller K, Murphy-Boesch J, Brown TR: Phospholipid metabolites in 1H-decoupled 31P MRS in vivo in human cancer: implications for experimental models and clinical studies. Anticancer Research 16: 1533-1538, 1996.
74. Yamagata NT, Miller BL, McBride D, Chang L, Chiang F, Nikas D, Osborne D, Buchthal SD: In vivo proton spectroscopy of intracranial infections and neoplasms. J Neuroimaging 4: 23-28, 1994.
75. Felber SR: H magnetic resonance spectroscopy in patients with intracranial tumors and cerebral ischemia. Radiologe 33: 626-632, 1993.
76. Lowry M, Manton D, Buckley D, Blackband S, Kerslakc R, Horsman A: Identification of intracranial tumors by localized proton MR spectroscopy (meeting abstract). Br J Radiol 66: 66, 1993.
77. Nakagawa T, Yamamoto M, Morito T, Hirata M, Sakae K, Hiraki Y, Matsumoto K, Higashi H, Nakagawa M, Ohmoto T: Usefulness of proton MR spectroscopy in differentiation of recurrent tumor and radiation necrosis (meeting abstract). International Congress of Radiation Oncology 1993 June 21-25, 1993, Kyo:-25, 1993, 1993.
78. Heesters MA, Kamman RL, Mooyaart EL, Go KG: Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy. J Neurooncol 17: 27-35, 1993.
79. Tzika AA, Vigneron DB, Ball WSJ, Dunn RS, Kirks DR: Localized proton MR spectroscopy of the brain in children. J Magn Reson Imaging 3: 719-729, 1993.
80. Kugel H, Heindel W, Ernestus RI, Bunke J, du Mesnil R, Friedmann G: Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 183: 701-709, 1992.
81. Sutton LN, Wang Z, Gusnard D, Lange B, Perilongo G, Bogdan AR, Detre JA, Rorke L, Zimmerman RA: Proton magnetic resonance spectroscopy of pediatric brain tumors. Neurosurgery 31: 195-202, 1992.
82. 1H NMR spectroscopy in 75 patients with a human brain tumor: clinical evaluation (meeting abstract). Neuroradiology 33: S140, 1991.
83. Fulham MJ, Bizzi A, Dietz MJ, Shih HH, Raman R, Sobering GS, Frank JA, Dwyer AJ, Alger JR, Di Chiro G: Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 185: 675-686, 1992.
84. 1H NMR spectroscopy in vivo and in vitro. J Comput Assist Tomogr 18: 705-713, 1994.
85. 1H NMR spectroscopy in vivo and in vitro. J Neurochem 63: 1538-1543, 1994.
86. Sijens PE, van Dijk P, Oudkerk M: Correlation between choline level and Gd-DTPA enhancement in patients with brain metastases of mammary carcinoma. Magn Reson Med 32: 549-555, 1994.
87. 1H MR spectroscopic imaging with metabolic classification in feature space (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 34: A1383, 1993.
88. Kamada K, Houkin K, Hida K, Matsuzawa H, Iwasaki Y, Abe H, Nakada T: Localized proton spectroscopy of focal brain pathology in humans: significant effects of edema on spin-spin relaxation time. Magn Reson Med 31: 537-540, 1994.
89. 1H MR spectroscopic imaging. Radiology 194: 271-276, 1995.
90. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, Macdonald JM, Konety B, Narayan P: Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 45: 459-466, 1995.
91. Kinoshita Y, Kajiwara H, Yokota A, Koga Y, Sutton LN: Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Neurosurgery 35: 606-13;, 1994.
92. Sonnewald U, Westergaard N, Isern E, Muller TB, Schousboe A, Petersen SB, Unsgard G: MRS evaluation of brain metabolites in extracts from cell cultures, human tumors and normal tissue from brain: cholesteryl ester, choline containing compounds and creatine as markers for development, differentiation and pathology. Int J Oncol 2: 545-555, 1993.
93. Sivaraja M, Turner C, Souza K, Singer S: Ex vivo two-dimensional proton nuclear magnetic resonance spectroscopy of smooth muscle tumors: advantages of total correlated spectroscopy over homonuclear J-correlated spectroscopy. Cancer Res 54: 6037-6040, 1994.
94. Kinoshita Y, Kajiwara H, Yokota A, Koga Y: Proton magnetic resonance spectroscopy of astrocytic tumors: an in vitro study. Neurol Med Chir Tokyo 33: 350-359, 1993.
95. 1H MRS of human brain tumor and normal glial cells. NMR Biomed 7: 111-120, 1994.
96. 31P NMR phospholipid characterization of intracranial tumors. Brain Res 649: 1-6, 1994.
97. 1H-magnetic resonance spectroscopy of pediatric posterior fossa tumors in vitro. J Neurosurg 81: 443-448, 1994.
98. Speckter H, Blumich B, Just M, Tromel U, Mitze M, Thelen M: in vitro NMR spectroscopy of healthy, mastopathically modified and carcinomatous breast tissue samples correlated with histological findings. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 161: 147-153, 1994.
99. Hanaoka H, Yoshioka Y, Ito I, Niitu K, Yasuda N: in vitro characterization of lung cancers by the use of H nuclear magnetic resonance spectroscopy of tissue extracts and discriminant factor analysis. Magn Reson Med 29: 436-440, 1993.
100. Mountford CE, Lean CL, Hancock R, Dowd S, Mackinnon WB, Tattersall MH, Russell P: Magnetic resonance spectroscopy detects cancer in draining lymph nodes. Invasion Metastasis 13: 57-71, 1993.
101. 1H MRS: Correlation with histopathology. Magnetic Resonance in Medicine 30: 525-533, 1993.
102. 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med 29: 149-157, 1993.
103. 31P magnetic resonance spectroscopy. J Urol 150: 2019-2024, 1993.
104. Preul MC, Caramanos Z, Collins DL, Villemure J-G, Leblanc R, Olivier A, Pokrupa R, Arnold DL: Accurate, non-invasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nature Medicine 2: 323-325, 1996.